Texas Retina’s New Waco Office Wins Outstanding Construction Award
The Associated General Contractors of America Texas Building Branch (AGCTBB) recently announced that they are awarding their annual “Healthcare 1 Outstanding Construction Award” to Mazanec Construction Company and Texas Retina’s new Waco
read more
Dr. Abbey Presented at the American Society of Retina Specialists 2023 Annual Meeting
Texas Retina Associates’ Ashkan M. Abbey, MD, recently presented at the 41st Annual Scientific Meeting of the American Society of Retina Specialists (ASRS) held in Seattle. ASRS is the largest organization of
read more
New Patient Portal System
Texas Retina Associates is in the process of transitioning to a new and improved patient portal system that will go live on Wednesday, August 9, 2023. This secure portal will provide you
read more
Why Do I Sometimes Have to Wait Beyond My Appointment Time to See a Physician?
We know you value your time, and we do, too. That is why we continually strive to see patients on a timely basis. However, certain retinal conditions are emergencies, and we pledge
read more
What is an Optical Coherence Tomography (OCT) Test?
Optical coherence tomography (OCT) is a non-invasive diagnostic imaging test similar to a computed tomography (CT) scan that allows your retina specialist to clearly see the retina and carefully map and measure
read more
Texas Retina Associates First in U.S. to Dose a Patient in the Phase 2 SIGLEC Trial
On June 1, 2023, Ashkan Abbey, MD, dosed the first patient in the Phase II SIGLEC Trial, a clinical study evaluating AVD-104, a potential new treatment for geographic atrophy (GA) from age-related
read more
Dr. Abbey Presents Phase 1 DAVIO Clinical Trial Results to the Association for Research in Vision and Ophthalmology
Dr. Abbey presented the results from the Phase 1 DAVIO trial at ARVO 2023, the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO). The trial was a first-in-human
read more Dr. Abbey Contributes to Real-world Study of Faricimab for Neovascular Age-related Macular Degeneration
The TRUCKEE study is a real-world, collaborative effort to investigate the efficacy, durability, and safety of a monoclonal antibody treatment called faricimab in patients suffering from neovascular age-related macular degeneration (nAMD) in
read more
Dr. Wang Participated in Roundtable Discussion on XIPERE Treatment for Macular Edema Associated with Uveitis
At the most recent American Academy of Ophthalmology (AAO) Annual Meeting in Chicago, Texas Retina Associates’ Robert Wang, MD, participated in a roundtable discussion with seven other retina specialists to share their
read more
Getting to Know Ocular Oncologist Timothy S. Fuller, MD
May is Ocular Melanoma Awareness Month. Ocular (uveal) melanoma is a rare but dangerous disease, and only a small number of doctors in the United States treat it. At Texas Retina Associates,
read more